On Monday, Protagonist Therapeutics reached a key performance benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 96, up from 90 the day before.
How To Use Stock Charts To Stay Profitable And Protected
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating of over 80 as they begin their biggest runs.
Protagonist Therapeutics has moved more than 5% past a 57.73 entry in a third-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Protagonist Therapeutics showed 0% earnings growth in the latest quarterly report. Sales gains came in at 33%. The next quarterly results are expected on or around Nov. 5.
The company holds the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and AbbVie are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
